Dataset from Randomized, Double-blind, 5 Period Cross Over Study Assessing Lung Function in Healthy Volunteers Following Single Inhalations of GSK573719 Inhalation Powder From Two Configurations of the Novel Dry Powder Inhaler

GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for the treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK573719, when administered via inhalation to humans supports the potential for use as a long acting bronchodilator.This is a randomized, double-blind, placebo-controlled, 5 period cross-over study in healthy male and female volunteers. The study will measure lung function after single inhaled doses from two configurations of the Novel Dry Powder Inhaler. Key assessments will include clinical relevant PD parameters: sGaw, FEV1

GSK573719是一种高亲和力特异性毒蕈碱受体（mAChR）拮抗剂，目前正被开发用于慢性阻塞性肺疾病（COPD）的治疗。该药物经吸入途径给药于人体后可维持长效作用，这一特性使其具备开发为长效支气管扩张剂的潜力。本研究为一项在健康男性及女性志愿者中开展的随机、双盲、安慰剂对照五周期交叉试验，将评估两种配置的新型干粉吸入器（Novel Dry Powder Inhaler）单次吸入给药后的肺功能表现。关键评估指标将涵盖具有临床相关性的药效动力学（PD）参数：sGaw与FEV1。